Physical and Cognitive Impairments at ICU Discharge are Associated with High Long-Term Mortality in ICU Survivors with Solid Malignancies: A Retrospective Cohort Study.
IF 2.8 3区 医学Q1 Pharmacology, Toxicology and Pharmaceutics
Su Yeon Lee, Jin Won Huh, Sang-Bum Hong, Chae-Man Lim, Jee Hwan Ahn
{"title":"Physical and Cognitive Impairments at ICU Discharge are Associated with High Long-Term Mortality in ICU Survivors with Solid Malignancies: A Retrospective Cohort Study.","authors":"Su Yeon Lee, Jin Won Huh, Sang-Bum Hong, Chae-Man Lim, Jee Hwan Ahn","doi":"10.2147/TCRM.S520206","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many ICU survivors experience post-ICU physical, cognitive, or mental impairments. In ICU survivors with solid malignancies, post-ICU impairments can impede further cancer treatments and negatively impact their outcomes. This study aimed to investigate post-ICU mortalities and their risk factors at ICU discharge in ICU survivors with solid malignancies.</p><p><strong>Methods: </strong>In this retrospective cohort study, adult patients with solid malignancies who were unexpectedly admitted to the medical ICU of a tertiary hospital between 2016 and 2022 and survived to ICU discharge were included. Data at ICU discharge were collected from electronic medical records. In-hospital and 1-year mortality and their risk factors were analyzed.</p><p><strong>Results: </strong>Of the 708 ICU survivors, 25.1% died in the hospital, and 61% died within one year. At ICU discharge, 20.9% had delirium, 3.8% had coma, and 80.6% had impaired mobility. Respiratory support, including bilevel positive airway pressure (BiPAP), high-flow nasal cannula (HFNC), or other oxygen therapies was used in 88.7% of patients. Delirium (adjusted OR 1.73; 95% CI 1.04-2.87; p = 0.035), coma (adjusted OR 5.63; 95% CI 2.09-16.17; p < 0.001), limited mobility (adjusted OR 2.41; 95% CI 1.22-5.14; p = 0.015), and use of BiPAP (adjusted OR 21.63; 95% CI 5.36-99.57; p < 0.001) or HFNC (adjusted OR 7.08; 95% CI 2.45-23.99; p < 0.001) were independently associated with in-hospital mortality. One-year survival was significantly lower in patients with delirium (35%, p < 0.001), coma (26%, p < 0.001), limited mobility (37%, p = 0.003), or those receiving respiratory support at ICU discharge (35%, p < 0.001).</p><p><strong>Conclusion: </strong>A considerable portion of ICU survivors with solid malignancies died in the hospital or within one year after ICU discharge in our study. Cognitive, mobility, and pulmonary impairments at ICU discharge were significant risk factors for both in-hospital and long-term mortality.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1121-1133"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296672/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S520206","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Many ICU survivors experience post-ICU physical, cognitive, or mental impairments. In ICU survivors with solid malignancies, post-ICU impairments can impede further cancer treatments and negatively impact their outcomes. This study aimed to investigate post-ICU mortalities and their risk factors at ICU discharge in ICU survivors with solid malignancies.
Methods: In this retrospective cohort study, adult patients with solid malignancies who were unexpectedly admitted to the medical ICU of a tertiary hospital between 2016 and 2022 and survived to ICU discharge were included. Data at ICU discharge were collected from electronic medical records. In-hospital and 1-year mortality and their risk factors were analyzed.
Results: Of the 708 ICU survivors, 25.1% died in the hospital, and 61% died within one year. At ICU discharge, 20.9% had delirium, 3.8% had coma, and 80.6% had impaired mobility. Respiratory support, including bilevel positive airway pressure (BiPAP), high-flow nasal cannula (HFNC), or other oxygen therapies was used in 88.7% of patients. Delirium (adjusted OR 1.73; 95% CI 1.04-2.87; p = 0.035), coma (adjusted OR 5.63; 95% CI 2.09-16.17; p < 0.001), limited mobility (adjusted OR 2.41; 95% CI 1.22-5.14; p = 0.015), and use of BiPAP (adjusted OR 21.63; 95% CI 5.36-99.57; p < 0.001) or HFNC (adjusted OR 7.08; 95% CI 2.45-23.99; p < 0.001) were independently associated with in-hospital mortality. One-year survival was significantly lower in patients with delirium (35%, p < 0.001), coma (26%, p < 0.001), limited mobility (37%, p = 0.003), or those receiving respiratory support at ICU discharge (35%, p < 0.001).
Conclusion: A considerable portion of ICU survivors with solid malignancies died in the hospital or within one year after ICU discharge in our study. Cognitive, mobility, and pulmonary impairments at ICU discharge were significant risk factors for both in-hospital and long-term mortality.
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.